Biofrontera Inc. Current Federal Tax Expense (Benefit)
Biofrontera Inc. (BFRI) reported Current Federal Tax Expense (Benefit) of -$10.47 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-03-19
- Biofrontera Inc. current federal tax expense (benefit) for fiscal 2025 was -$10.47M.
- Biofrontera Inc. current federal tax expense (benefit) for fiscal 2024 was -$17.23M.
- Biofrontera Inc. current federal tax expense (benefit) for fiscal 2023 was -$20.12M.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$10.47M 10-K · filed 2026-03-19 |
| 2024-12-31 | -$17.23M 10-K · filed 2026-03-19 |
| 2023-12-31 | -$20.12M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |